Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary

Clin Exp Rheumatol. 2021 Jan-Feb;39(1):223. doi: 10.55563/clinexprheumatol/rl668e. Epub 2020 May 20.

Authors

Giulia Lavinia Fonti¹, Maria Sole Chimenti², Elisabetta Greco², Laura Boffa³, Paola Conigliaro², Paola Triggianese², Roberto Perricone²

Affiliations

¹ Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. [email protected].
² Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
³ Department of Neurosciences, MS Centre, Tor Vergata University, Rome, Italy.

PMID: 32452349
DOI: 10.55563/clinexprheumatol/rl668e

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antirheumatic Agents* / adverse effects
Humans
Multiple Sclerosis* / drug therapy
Spondylitis, Ankylosing* / complications
Spondylitis, Ankylosing* / diagnosis
Spondylitis, Ankylosing* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
secukinumab